- Stocks
- Pharma & Healthcare
- Sai Parenterals
Sai Parenterals share price
NSE: SAIPARENTPharma & HealthcareDrug Manufacturers - General
Sai Parenterals at a glance
Sai Parenterals (NSE: SAIPARENT) closed at ₹461.90 on 22 Oct 2026, down 1.31% on the day. With a market capitalisation of ₹2,041 Cr, it ranks 1140th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 103.6× trailing earnings, against a return on equity of 2.9% in FY26. Its 52-week range is ₹400.00 (2 Apr 2026) to ₹706.00 (2 Jul 2026); the last close is 34.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹198 Cr and net profit ₹13 Cr, on a consolidated basis. Promoters held 51.16% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,041 CrRank 1140 on NSE
- P/E (trailing)
- 103.6×
- Price to book
- 0×FY26
- ROE
- 2.9%FY26
- ROCE
- 3.6%FY26
- Debt to equity
- 0.65FY26
- Net profit margin
- 3.7%FY26
- Book value / share
- ₹111.08FY26
- 52-week high
- ₹706.002 Jul 2026
- 52-week low
- ₹400.002 Apr 2026
- RSI (14-day)
- 33.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.31% | −7.0% | −9.6% | −15.8% | — |
Sai Parenterals quarterly results
| Quarter | Q3 FY26 | Q4 FY26 |
|---|---|---|
| Revenue | ₹96 Cr | ₹198 Cr |
| Revenue YoY | — | — |
| Net profit | −₹7 Cr | ₹13 Cr |
| Net profit YoY | — | — |
| Net margin | −6.9% | 6.6% |
| EPS | −₹1.51 | ₹4.02 |
Sai Parenterals financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹97 Cr | ₹154 Cr | ₹163 Cr | — |
| Operating profit | ₹7 Cr | ₹13 Cr | ₹20 Cr | — |
| Net profit | ₹4 Cr | ₹8 Cr | ₹14 Cr | — |
| EPS (₹) | ₹6.00 | ₹11.00 | ₹5.00 | — |
| Cash from operations | −₹13 Cr | −₹30 Cr | ₹33 Cr | — |
| Total debt | ₹26 Cr | ₹39 Cr | ₹14 Cr | ₹90 Cr |
| Shareholders' equity | ₹31 Cr | ₹75 Cr | ₹94 Cr | ₹491 Cr |
Sai Parenterals shareholding pattern
| Holder | 31 Mar 2026 | 1 Apr 2026 | 30 Jun 2026 |
|---|---|---|---|
| Promoters | 51.16% | 51.16% | 51.16% |
| Foreign institutions | 5.73% | 5.73% | 4.03% |
| Domestic institutions | 12.86% | 12.86% | 8.53% |
| Non-institutions | 30.26% | 30.26% | 36.29% |
Sai Parenterals vs peers
The listed Pharma & Healthcare companies nearest to Sai Parenterals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SYNCOMFSyncom Formulations (India) | ₹22.83 | +3.21% | +38.8% | ₹2,146 Cr | 28.2 | — |
| INDOCOIndoco Remedies | ₹230.55 | +0.74% | −21.9% | ₹2,128 Cr | — | — |
| PANACEABIOPanacea Biotec | ₹335.85 | −1.22% | −24.2% | ₹2,057 Cr | — | — |
| SAKARSakar Healthcare | ₹923.90 | +2.66% | +156.4% | ₹2,056 Cr | 67.6 | — |
| SAIPARENTSai Parenterals | ₹461.90 | −1.31% | — | ₹2,041 Cr | 103.6 | — |
| BETABeta Drugs | ₹1,773.00 | +5.60% | +3.3% | ₹1,966 Cr | 43.4 | — |
| HESTERBIOHester Biosciences | ₹2,165.00 | −0.37% | +25.4% | ₹1,842 Cr | 32 | — |
Ask anything about Sai Parenterals
Pivot answers on the live chart with evidence you can check, and tests strategies against SAIPARENT's own history. Try: “Why has SAIPARENT moved over the last three months?” · “Backtest a 50-day moving-average crossover on SAIPARENT over five years” · “Compare SAIPARENT with SYNCOMF on margins and valuation”
Frequently asked questions about Sai Parenterals
What is the share price of Sai Parenterals today?
Sai Parenterals (NSE: SAIPARENT) last closed at ₹461.90 on 22 Oct 2026. Its 52-week high is ₹706.00 and its 52-week low is ₹400.00.
What is the market cap of Sai Parenterals?
Sai Parenterals' market capitalisation is ₹2,041 Cr (₹2,041 Cr) at the 22 Oct 2026 close, ranking 1140th among the NSE companies Pivot tracks.
What is the P/E ratio of Sai Parenterals?
Sai Parenterals trades at a trailing P/E of 103.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 43.4.
What is the ROE and ROCE of Sai Parenterals?
Return on equity was 2.9% in FY26 and return on capital employed was 3.6% in FY26 (consolidated figures).
Is Sai Parenterals a debt-free company?
No. Sai Parenterals' debt-to-equity ratio was 0.65 in FY26, with total debt of ₹90 Cr.
What were Sai Parenterals' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Sai Parenterals reported revenue of ₹198 Cr and net profit of ₹13 Cr.
What is the shareholding pattern of Sai Parenterals?
As of 30 Jun 2026: promoters 51.16%, foreign institutions 4.03%, domestic institutions 8.53%, non-institutions 36.29%.
Who are Sai Parenterals' competitors?
The listed Pharma & Healthcare companies closest to Sai Parenterals by market cap are Syncom Formulations (India), Indoco Remedies, Panacea Biotec, Sakar Healthcare, Beta Drugs and Hester Biosciences.
Is Sai Parenterals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sai Parenterals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAIPARENT against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text